Navigation Links
PDI Announces Group DCA's Launch of eDetailing Across Apple® and Android™ Mobile Devices
Date:4/25/2011

PARSIPPANY, N.J., April 25, 2011 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced that Group DCA has expanded its proprietary DIAGRAM™ software platform to enable eDetail delivery on popular mobile devices including the iPad®, iPod touch® and iPhone®(1) and Android™(2)-based phones.

"With physicians adopting smartphones and other mobile devices even faster than the general population, we are moving quickly to meet their information demands across all key media," said Jo Ann Saitta, SVP of Information Technology for PDI. "This extension of eDetailing to mobile programs is consistent with our growth strategy and positions PDI and Group DCA well across a broad range of communications channels to deliver our clients' messages to healthcare professionals."

Noted Ron Scalici, Group DCA Chief Innovations Officer, "Not only can our clients now reach physicians via multiple devices, but they can be assured that our content will be innovative and tailored specifically to particular platforms, while remaining confident in our commitment to complying with the requirements and appropriate disclosure standards of The Division of Drug Marketing, Advertising, and Communications (DDMAC) of the U.S. Food and Drug Administration (FDA)."

Group DCA's eDetailing programs utilize its proprietary DIAGRAM™ software to create a customized, self-initiated experience for each participant based upon their attitudes, preferences and information needs. An integrated data warehouse and centralized content library allow for greater efficiency in content creation and dissemination, and easy adaption of approved marketing materials across multiple device platforms. These capabilities facilitate the development and execution of additional outreach efforts under a broader, multi-channel strategy that may include PDI's field sales represe
'/>"/>

SOURCE PDI, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Sanofi Pasteur Announces FDA Approval of Menactra Meningococcal Conjugate Vaccine Indication for Infants
2. iMD Companies, Inc. Announces Expansion of OMI Operations
3. Jazz Pharmaceuticals Announces First Quarter 2011 Results Conference Call on May 3
4. Important Drug Product Notice: Luitpold Pharmaceuticals, Inc. Announces Temporary Suspension of Distribution and Manufacture of Drug Products
5. Misonix Announces New Distribution Agreement for Colombia
6. Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast
7. Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder
8. China Botanic Pharmaceutical Announces Plans to Switch to Renewable Bio-Fuel - Straw Pellets
9. China Shenghuo Announces New Chief Financial Officer
10. ULURU Inc. Announces Going Concern Qualification
11. Boston Scientific Announces Results for First Quarter Ended March 31, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013  Lehigh Valley Health Network has announced the ... adding to its existing arsenal of five 5-foot-5 germ-killing ... within the network, LVHN is now deploying the largest ... superbugs and provide the best possible patient care available. ... TRU-D – the signature product of Memphis ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
(Date:5/21/2013)... , May 21, 2013  BioRestorative Therapies, Inc. ... sciences company focused on developing stem cell based therapies ... Weinreb , its President and CEO, will be ... The conference will be held on Thursday, May 30, ... E 42nd Street in New York City.  Mr. Weinreb,s ...
Breaking Medicine Technology:Lehigh Valley Expands Fleet of Superbug-Slaying Robots 2Lehigh Valley Expands Fleet of Superbug-Slaying Robots 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3
... , , , ... academic, private and government cancer drug discovery efforts , ... Research Institute today announced that it has been selected as ... Institute,s (NCI) Chemical Biology Consortium (CBC)--a program meant to coordinate ...
... , , , ... N.J., Aug. 19 Newly published data in The New ... (letrozole tablets) following surgery as an optimal treatment approach versus tamoxifen ... , The data include an analysis from the ...
Cached Medicine Technology:Southern Research to Play Key Role in the Federal Government's Search for New Cancer Therapies 2Southern Research to Play Key Role in the Federal Government's Search for New Cancer Therapies 3Southern Research to Play Key Role in the Federal Government's Search for New Cancer Therapies 4Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 2Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 3Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 4Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 5Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 6Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 7Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 8Results In 'The New England Journal Of Medicine' Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery 9
(Date:5/21/2013)... Nearly 40 Platinum Supplemental Insurance Sales Representatives ... Los Cabos, Mexico, Feb. 23-March 1, 2013, to help renovate ... The facility serves meals and provides a social outlet for ... , Platinum Vice President, Mike Muench, says that the idea ... , “Platinum got its start selling long-term care insurance ...
(Date:5/21/2013)... May 21, 2013 Dimensional Insight, a ... announced that Western Maryland Health System, a ... The Diver Solution™ (Diver) to help it analyze its ... first customer to purchase Diver through Dimensional Insight’s recently ... Like most hospitals, Western Maryland has massive amounts of ...
(Date:5/21/2013)... Tools4ever, the market leader in Identity & Access ... Password Management (SSRPM) suitable for BYOD. With the latest ... on mobile systems i.e.; laptops, tablets, handheld computers and ... Windows passwords anywhere, anytime. Once the end user has ... then reset his or her own password. , ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Thousands of ... from the lung condition known as chronic obstructive ... that patients placed on the common antibiotic azithromycin ... due to flare-ups of the disease. "Given ... of such events is critical," said Victoria Richards, ...
(Date:5/21/2013)... ─ Clinical measurement of physical activity appears to ... patients with chronic obstructive pulmonary disease (COPD) will ... study conducted by researchers in Connecticut. The study ... levels of inactivity with an increased incidence of ... of the study will be presented at the ...
Breaking Medicine News(10 mins):Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 2Health News:Platinum Supplemental Insurance Gives Back at Casa De Dia, Mexico 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Tools4ever’s password reset software ready for BYOD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 2Health News:Long-Term Use of Antibiotic May Help Those With COPD 3Health News:Exercise levels may predict hospitalizations in COPD population 2
... Dec. 13, Speaker Nancy Pelosi,issued the following statement ... Leader George Mitchell, which found widespread use,of steroids and ... Mitchell Report tells a troubling story of how many ... the fans of our national,pastime by using steroids and ...
... Poll Shows Rural Seniors Want E-Prescribing in Medicare, ... so many issues, promoting electronic prescribing (e-prescribing) in,Medicare ... and Democrats can,agree on. "The Medicare Electronic Medication ... require that Medicare physicians begin to,prescribe electronically, will ...
... The University of Illinois at Chicago College of Nursing has ... people as they transition to the end of life. ... the science of care for people of all ages facing ... funded through a $2.4 million grant from the National Institute ...
... side effects, including heart trouble , , THURSDAY, Dec. 13 ... Andy Pettitte, Houston Astros All-Star shortstop Miguel Tejada and ... players cited in a highly anticipated report into the ... , The report climaxed a 20-month probe by former ...
... 13 The Quantum Group,Inc. (Amex: QGP, QGP.U) ... its registered public offering, raising $13.2 million in,gross ... initiated trading,on the American Stock Exchange (AMEX) of ... "QGP.U." In addition, Quantum common shares,formerly traded on ...
... Dec. 13 Repligen Corporation,(Nasdaq: RGEN ) ... has been,elected to its Board of Directors. Dr. ... and regulatory expertise in the,development of therapeutics for ... very pleased to welcome an executive with Earl,s ...
Cached Medicine News:Health News:One Thing Washington Can Agree On: Time for E-Prescribing in Medicare 2Health News:One Thing Washington Can Agree On: Time for E-Prescribing in Medicare 3Health News:New UIC center to study end-of-life transition 2Health News:New UIC center to study end-of-life transition 3Health News:Report Finds 'Widespread Steroid Use in Baseball' 2Health News:Report Finds 'Widespread Steroid Use in Baseball' 3Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 2Health News:The Quantum Group, Inc. Completes $13.2 Million Public Offering and Initiates Trading on the American Stock Exchange Under Symbol 'QGP' 3Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 2Health News:Repligen Elects Earl Henry, M.D. to the Board of Directors 3
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... for small and medium volume laboratories, as ... System offers the speed, simplicity and flexibility ... Compact yet powerful, the Elecsys 1010 system ... response assays to routine testing without sacrificing ...
Sample throughput of up to 80 tests per hour (4 modules). Low maintenance requirements. Continuous random access. 25 - 100 channels on board. 1008 tests or 6 hours of walkaway operation....
Medicine Products: